Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Ottmann

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Blood|August 23, 2017
Hematopoietic stem cell involvement in <i>BCR-ABL1-</i>positive ALL as a potential mechanism of resistance to blinatumomab therapyInga Nagel, Marius Bartels, Johannes Duell, et al.
Annals of Hematology|April 29, 2025
Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemiaAnna Turkina, Olga Vinogradova, Elza Lomaia, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factorKatharina Wagner, Frederik Damm, Gudrun Göhring, et al.
Investigational New Drugs|June 1, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Investigational New Drugs|June 25, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
The Lancet. Haematology|March 19, 2018
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trialJennifer R Brown, Mehdi Hamadani, John Hayslip, et al.
The Journal of Experimental Medicine|March 21, 2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLFaisal Basheer, George Giotopoulos, Eshwar Meduri, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Blood|August 23, 2017
Hematopoietic stem cell involvement in <i>BCR-ABL1-</i>positive ALL as a potential mechanism of resistance to blinatumomab therapyInga Nagel, Marius Bartels, Johannes Duell, et al.
Annals of Hematology|April 29, 2025
Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemiaAnna Turkina, Olga Vinogradova, Elza Lomaia, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factorKatharina Wagner, Frederik Damm, Gudrun Göhring, et al.
Investigational New Drugs|June 1, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Investigational New Drugs|June 25, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
The Lancet. Haematology|March 19, 2018
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trialJennifer R Brown, Mehdi Hamadani, John Hayslip, et al.
The Journal of Experimental Medicine|March 21, 2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLFaisal Basheer, George Giotopoulos, Eshwar Meduri, et al.
Pageof 6